Continuing Medical Education Questions: March 2023

Abstract

Article Title: Fecal Microbiota Transplantation Across the Lifespan- Balancing Efficacy, Safety, and Innovation

LEARNING OBJECTIVE

After this activity, the participant will be able to demonstrate knowledge about the safety and efficacy of fecal microbiota transplantation (FMT) in adults and children with recurrent Clostridioides difficile infection and appraise the efficacy of novel live bacterial products.

QUESTION 1

Based on the article, which of the following is a correct statement about the safety of FMT?

1. There is no risk of transmission of infections with FMT
2. Serious adverse events occur in approximately 5% of patients
3. Adverse events can be avoided with delivery via the upper gastrointestinal tract
4. FMT has been shown to cause rheumatoid arthritis, Sjogren's syndrome, and idiopathic thrombocytopenic purpura

QUESTION 2

In phase 3 randomized trials, the use of novel live bacterial products (RBX2660 and SER-109) in patients with C. difficile infection resulted in which of the following?

1. Lower rates of recurrent C. difficile infection
2. Higher response rates in children as compared with adults
3. Lower rates of fulminant C. difficile infection
4. Shorter time to recurrence of C. difficile infection as compared with direct installation of FMT in the gastrointestinal tract

QUESTION 3

Which of the following is a correct statement regarding the use of FMT in children?

1. Success rates with the use of FMT for the treatment of C. difficile infection are lower as compared to adults.
2. Success rates for treatment of C. difficile infection are higher when using fresh stool as compared with frozen stool.
3. Safety and efficacy of FMT in children are evaluated in randomized controlled trials (RCTs).
4. FMT in children has a higher risk of complications as compared with adults.